Patents Represented by Attorney Patricia Anne Perkins
-
Patent number: 7235637Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: May 10, 2004Date of Patent: June 26, 2007Assignee: Immunex CorporationInventors: John E. Sims, Blair R. Renshaw
-
Patent number: 7232660Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: October 2, 2003Date of Patent: June 19, 2007Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage
-
Patent number: 7223565Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: May 10, 2004Date of Patent: May 29, 2007Assignee: Immunex CorporationInventors: John E. Sims, Blair R. Renshaw
-
Patent number: 7217540Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: July 9, 2004Date of Patent: May 15, 2007Assignee: Immunex CorporationInventors: John E. Sims, Dirk E. Smith, Teresa L. Born
-
Patent number: 7186818Abstract: Isolated receptors, nucleic acids encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors or agonists thereof.Type: GrantFiled: April 25, 2002Date of Patent: March 6, 2007Assignee: Immunex CorporationInventors: Anne-Renee Van Der Vuurst De Vries, Laurent J. Galibert
-
Patent number: 7169891Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.Type: GrantFiled: April 27, 2001Date of Patent: January 30, 2007Assignee: Immunex CorporationInventors: Timothy A Bird, David J Cosman
-
Patent number: 7169581Abstract: A novel polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.Type: GrantFiled: May 15, 2003Date of Patent: January 30, 2007Assignee: Immunex CorporationInventors: John E Sims, Teresa L Born
-
Patent number: 7122183Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.Type: GrantFiled: August 26, 2003Date of Patent: October 17, 2006Assignee: Immunex CorporationInventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
-
Patent number: 7033783Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: June 6, 2001Date of Patent: April 25, 2006Assignee: Immunex Corp.Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
-
Patent number: 6949359Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.Type: GrantFiled: August 20, 1999Date of Patent: September 27, 2005Assignee: Immunex CorporationInventors: John E. Sims, Dirk E. Smith
-
Patent number: 6852486Abstract: A poxvirus protein designated A41L binds to leukocyte common-antigen-related protein (LAR). A41L is a secreted protein that can be purified from the culture supernatant of cells infected with certain poxviruses, or produced using recombinant DNA techniques. A41L polypeptides and LAR polypeptides, and nucleic acids encoding them, are provided herein. Also provided are methods of using such polypeptides and nucleic acids.Type: GrantFiled: July 3, 2002Date of Patent: February 8, 2005Assignee: Immunex Corp.Inventors: Craig A. Smith, Raymond G. Goodwin
-
Patent number: 6838290Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.Type: GrantFiled: October 2, 2001Date of Patent: January 4, 2005Assignee: Immunex CorporationInventors: John E. Sims, Dirk E. Smith
-
Patent number: 6794173Abstract: Isolated Dendritic Cell Transmembrane Serine Proteases (DCTSPs), DNAs encoding such DCTSPs, and pharmaceutical and/or diagnostic compositions made therefrom, are disclosed. The isolated DCTSPs can be used to hydrolyze peptide bonds. The DCTSPs are also useful in screening for inhibitors or agonists thereof.Type: GrantFiled: June 20, 2002Date of Patent: September 21, 2004Assignee: Immunex CorporationInventors: Dirk M. Anderson, G. Duke Virca
-
Patent number: 6753166Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.Type: GrantFiled: October 11, 2001Date of Patent: June 22, 2004Assignee: Immunex CorporationInventors: John E. Sims, Blair R. Renshaw
-
Patent number: 6680057Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.Type: GrantFiled: April 14, 2000Date of Patent: January 20, 2004Assignee: Immunex CorporationInventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
-
Patent number: 6667039Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplasdic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.Type: GrantFiled: July 28, 2000Date of Patent: December 23, 2003Assignee: Immunex CorporationInventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
-
Patent number: 6652854Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.Type: GrantFiled: August 3, 2001Date of Patent: November 25, 2003Assignee: Immunex CorporationInventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
-
Patent number: 6632637Abstract: There is disclosed an expression vector utilizing an internal polyadenylation signal. The internal polyadenylation signal is inserted between a DNA encoding a protein of interest and a DNA encoding a selectable marker, and allows a single promoter to generate both monocistronic messages and dicistronic messages. Similar, multicistronic vectors can also be prepared. Also disclosed are methods of using the expression vector utilizing an internal polyadenylation signal, host cells transfected therewith, stable pools of cells transfected with an expression vector utilizing an internal polyadenylation signal, and clones of such transfected cells.Type: GrantFiled: October 12, 2000Date of Patent: October 14, 2003Assignee: Immunex CorporationInventor: Jeffrey T. McGrew
-
Patent number: 6589764Abstract: A polypeptide that functions as an IL-18 receptor is disclosed. The receptor is multimeric and includes at least one AcPL polypeptide, or fragment thereof, and at least one IL-1Rrp1 polypeptide, or fraction thereof. The receptor binds IL-18 and finds use in inhibiting biological activities mediated by IL-18.Type: GrantFiled: July 21, 2000Date of Patent: July 8, 2003Assignee: Immunex CorporationInventors: John E. Sims, Teresa L. Born
-
Patent number: 6521740Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.Type: GrantFiled: May 16, 1995Date of Patent: February 18, 2003Assignee: Immunex CorporationInventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower